NervGen Pharma

NervGen Pharma EBIT Margin

EBIT Margin (Operating Margin) of NervGen Pharma (NGEN.V) as of Oct 18, 2026.

EBIT Margin

-

Last updated:

EBIT Margin (Operating Margin) of NervGen Pharma is 2026 - . EBIT Margin (Operating Margin) of NervGen Pharma was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NervGen Pharma Stock analysis

What does NervGen Pharma do? NervGen Pharma Corp, based in Vancouver, Canada, operates in the Health Care sector as a regenerative medicine company. It focuses on discovering, developing, and commercializing therapeutics for nerve damage, including spinal cord and peripheral nerve injuries. The company is advancing its lead compound NVG-291 for spinal cord injury, Alzheimer’s disease, and multiple sclerosis. With 10 full-time employees, it has two wholly owned subsidiaries, NervGen US Inc. and NervGen Australia Pty Ltd. NervGen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NervGen Pharma stock

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) NervGen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s NervGen Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NervGen Pharma

All Key Metrics — NervGen Pharma